



(12) Translation of
European patent specification

(11) NO/EP 3197493 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/395 (2006.01)
A61K 31/282 (2006.01)
A61P 35/00 (2006.01)
C07K 16/22 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.07.19
(80) Date of The European Patent Office Publication of the Granted Patent 2021.03.10
(86) European Application Nr. 15777810.1
(86) European Filing Date 2015.09.25
(87) The European Application's Publication Date 2017.08.02
(30) Priority 2014.09.25, US, 201462055203 P
(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73) Proprietor Aveo Pharmaceuticals Inc., 1 Broadway 14th Floor, Cambridge, MA 02142, USA
(72) Inventor GYURIS, Jeno, 139 Lexington Road, Lincoln, MA 01773, USA
LERNER, Lorena, 37 Westgate Road, Newton Centre, MA 02459, USA
LIN, Jie, 4 Willow Terrace, West Roxbury, MA 02132, USA
(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT**
(56) References
Cited: WO-A1-2014/100689
WO-A1-2005/099746
VICKY W. W. TSAI ET AL: "Anorexia/cachexia of chronic diseases: a role for the TGF-&bgr; family cytokine MIC-1/GDF15", JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE, vol. 3, no. 4, 31 December 2012 (2012-12-31), pages 239-243, XP055105895, ISSN: 2190-5991, DOI: 10.1007/s13539-012-0082-6
JOHNEN HEIKO ET AL: "Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 11, 1 November 2007 (2007-11-01), pages 1333-1340, XP002607045, ISSN: 1078-8956, DOI: 10.1038/NM1677 [retrieved on 2007-11-04]
JEFFREY S DAMRAUER ET AL: "Chemotherapy-induced muscle wasting: association with NF-kappaB cancer cachexia", BASIC APPLIED MYOLOGY, UNIPRESS, IT, vol. 18, no. 5, 1 January 2008 (2008-01-01), pages 139-148, XP002733150, ISSN: 1120-9992

THOMAS ET AL: "Loss of skeletal muscle mass in aging: Examining the relationship of starvation, sarcopenia and cachexia", CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 26, no. 4, 26 July 2007 (2007-07-26), pages 389-399, XP022159281, ISSN: 0261-5614, DOI: 10.1016/J.CLNU.2007.03.008

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Minst ett kjemoterapeutisk middel mot kreft og minst ett anti-GDF15
antistoff eller GDF15-bindende fragment derav for anvendelse ved
5 behandling av cellegiftindusert kakeksi ved å øke totaloverlevelsen hos
et individ som har cellegiftindusert kakeksi.

2. Det minst ene antikreftmiddel og det minst ene anti-GDF15-antistoff
eller GDF15-bindende fragment derav for anvendelse ifølge krav 1, hvor
10 antikreftmidlet er valgt fra gruppen bestående av: capecitabin,
gemcitabin, dokosorubicin, cisplatin, carboplatin og oksaliplatin.

3. Det minst ene kjemoterapeutiske middel mot kreft og det minst ene
anti-GDF15-antistoff eller GDF15-bindende fragment derav for
15 anvendelse ifølge krav 1, hvor administrering av anti-GDF15-antistoffet
eller GDF15-bindende fragment derav og det kjemoterapeutiske anti-
kreftmidlet forlenger gjennomsnittlig overlevelse i en første
pasientpopulasjon med cellegiftindusert kakeksi i forhold til en annen
pasientpopulasjon med cellegiftindusert kakeksi som ikke mottar
20 GDF15-modulatoren.